Effect of Abdominal Obesity on Insulin Resistance and the Components of the Metabolic Syndrome: Evidence Supporting Obesity as the Central Feature

Obesity Surgery

Volumn 13, Issue 5, 2003, Pages 699-705

  Türkoglu, Çavlan ^a   Duman, Belgin Süsleyici ^a   Günay, Demet ^b   Çagatay, Penbe ^c   Özcan, Remzi ^a   Büyükdevrim, A Sevim ^b  

^a KADIR HAS UNIVERSITY   (Turkey)

^b FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Diabetes type 2; Hyperinsulinemia; Insulin resistance; Macro and microangiopathy; Metabolic syndrome; Morbid obesity; Obesity

Indexed keywords

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY FAT; CLINICAL FEATURE; CONTROLLED STUDY; DYSLIPIDEMIA; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

ABDOMEN; BODY WEIGHT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY;

EID: 10744233405     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089203322509255     Document Type: Article

References (33)

1. Mykkänen L, Kuusisto J, Pyörälä K et al. Cardiovascular disease risk factors as predictors of Type 2 (non-insulin- dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553-9.
2. Morrish NJ, Wang SL, Stevens LK et al. WHO Multinational Study Group: Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001; 44 (Suppl 2): S14-S21.
3. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1999; 42: 499-518.
4. Onat A. Türkiye Kalp Raporu (Report for Cardiovascular Disorders in Turkey) 2000, Türk Kardioloji Dernegi (Turkish Cardiology Association), Yenilik Basimevi, Istanbul, 2000.
5. Lebovitz HE. Sulfonylurea drugs. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders, 2nd edn. Alexandria, Virginia: ADA Inc. 1994: 116-23.
6. Charbonnel B, ed. Suivi du patient diabétique de type 2 à l'exclusion du suivi des complications. Recommandations de l'ANAES. Diabetes & Metabolism 1999; 25 (Supp 2): 1-64.
7. Matthews DR, Hosker JP, Rudensky AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-9.
8. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Geneva: World Health Organization, 1999.
9. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2313-46.
10. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diab Care 2002; 25 (Supp 1): S74-S77.
11. Angelico F, Del Ben M, Giampaoli S et al. High prevalence of obesity in a rural community of central Italy. In: Baba S, Zimmet P, eds. World Data Book of Obesity. Excerpta Medica, Int Congress, Series 959, Amsterdam 1990: 5-9.
12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diab Med 1998; 15: 539-53.
13. Hume R. Prediction of lean body mass from height and weight. J Clin Path 1966; 19: 389-95.
14. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerane and insulin sensitivity. Diab Care 2000; 23: 57-63.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diab Care 1999; 22: 1462-70.
16. Devrim S, Koniçe M, Sencer E et al. Serum immunoreactive insulin response to oral glucose and intravenous sodium tolbutamide administration in relation to obesity. Israel J Med Sci 1972; 8: 815-20.
17. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
18. Svedberg J, Bjöntorp P, Smith U et al. Free-fatty acid inhibition of insulin binding, degradation, and action in isolated rat hepatocytes. Diabetes 1990; 39: 570-4.
19. Bonadonna R, Groop L, Kraemer N et al. Obesity and insulin resistance in man: a dose response study. Metabolism 1990; 39: 452-9.
20. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab Care 1991; 14: 173-94.
21. Castagneto M, De Gaetano A, Mingrone G et al. Normalization of insulin sensitivity in the obese patient after stable weight reduction with biliopancreatic diversion. Obes Surg 1994; 4: 161-8.
22. Carey DG, Jenkins AB, Campbell LV et al. Abdominal fat and insulin resistance in normal and overweight women. Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-8.
23. Nedelnikova K, Svacina S, Haas T et al. Influence of metabolic state and diabetes on the outcome at the end of first year after gastric banding. Obes Surg 2000; 10: 372-5.
24. Bacci V, Basso MS, Greco F et al. Modifications of metabolic and cardiovascular risk factors after weight loss induced by laparoscopic gastric banding. Obes Surg 2002; 12: 77-82
25. Shuldiner AR, Yang R, Gong DW. Resistin, obesity, and insulin resistance - the emerging role of the adipocyte as an endocrine organ. N Eng J Med 2001; 345: 1345-6.
26. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-6.
27. Reaven GM. The fourth Musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 1995; 38: 3-13.
28. Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Eng J Med 1987; 317: 350-7.
29. Santen RJ, Willis PW, Fajans SS. Atherosclerosis in diabetes mellitus. Correlation with serum lipid levels, adiposity, and serum insulin level. Arch Intern Med 1972; 130: 833-43.
30. Adami GF, Ravera G, Marinari GM et al. Metabolic syndrome in severely obese patients. Obes Surg 2001; 11: 543-45.
31. Maison P, Byrne CD, Hales CN et al. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diab Care 2001; 24: 1758-63.
32. Pyörälä K, Uustipa M, Laakso M et al. Macrovascular complications in relation to hyperinsulinaemia in non-insulin-dependent diabetes mellitus. Diabete & Metabolisme (Paris) 1987; 13: 345-9.
33. Stout RW. Insulin and atheroma: 20-yr perspective. Diab Care 1990; 13: 631-54.